A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice

CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5

Source: Clinical Genitourinary Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research